Intercept Pharmaceuticals Upgraded to Outperform by Leerink Swann (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities researchers at Leerink Swann from a “market perform” rating to an “outperform” rating in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm currently has a $445.00 price target on the stock, up from their previous price target of $270.00. Leerink Swann’s price target indicates a potential upside of 87.62% from the stock’s previous close.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 10,000 shares of Intercept Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total transaction of $2,267,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 16.59% on Tuesday, hitting $276.52. The stock had a trading volume of 6,088,050 shares. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock has a 50-day moving average of $232.6 and a 200-day moving average of $291.7. The company’s market cap is $5.831 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-14.82 EPS for the current fiscal year.
ICPT has been the subject of a number of other recent research reports. Analysts at Deutsche Bank upgraded shares of Intercept Pharmaceuticals to an “outperform” rating in a research note on Tuesday. They now have a $500.00 price target on the stock, up previously from $395.00. Separately, analysts at Nomura upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 29th. They now have a $323.00 price target on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $503.00.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.